LLY analyst estimates
Eli Lilly (LLY) analyst ratings, the average price target and its range, and every firm's latest call.
LLY analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 30, 2026 | Truist Financial | Eli Lilly (LLY) PT Raised to $1,612 at Truist Securities | $1,612.00 |
| Oct 30, 2026 | Wells Fargo | Eli Lilly (LLY) PT Raised to $1,500 at Wells Fargo | $1,500.00 |
| Oct 30, 2026 | KeyBanc | Eli Lilly (LLY) PT Raised to $1,497 at BofA Securities | $1,497.00 |
| Oct 30, 2026 | BMO Capital | Eli Lilly (LLY) PT Raised to $1,650 at BMO Capital | $1,650.00 |
| Oct 30, 2026 | UBS | Eli Lilly (LLY) PT Raised to $1,625 at UBS | $1,625.00 |
| Oct 30, 2026 | Argus Research | Eli Lilly (LLY) PT Raised to $1,550 at Argus | $1,550.00 |
| Oct 30, 2026 | RBC Capital | Eli Lilly (LLY) PT Raised to $1,600 at Freedom Broker | $1,600.00 |
| Oct 26, 2026 | Bernstein | Eli Lilly price target raised to $1,450 from $1,385 at Bernstein | $1,450.00 |
| Oct 21, 2026 | Leerink Partners | Eli Lilly price target raised to $1,316 from $1,309 at Leerink | $1,316.00 |
| Oct 20, 2026 | Goldman Sachs | Eli Lilly price target raised to $1,413 from $1,371 at Goldman Sachs | $1,413.00 |
| Oct 8, 2026 | Cantor Fitzgerald | Eli Lilly price target raised to $1,440 from $1,410 at Cantor Fitzgerald | $1,440.00 |
| Oct 7, 2026 | Morgan Stanley | Eli Lilly price target raised to $1,430 from $1,419 at Morgan Stanley | $1,430.00 |
| Sep 18, 2026 | Guggenheim | Eli Lilly (LLY) PT Raised to $1,284 at Guggenheim | $1,284.00 |
| Sep 15, 2026 | Berenberg Bank | Berenberg Upgrades Eli Lilly (LLY) to Buy | $1,400.00 |
| Sep 10, 2026 | HSBC | Eli Lilly price target raised to $940 from $850 at HSBC | $940.00 |
- 22 firms rate LLY: 20 buy, 1 hold, 1 sell.
- The average price target is $1,447.13 from 15 analysts, from $940.00 to $1,650.00.
Updated 2026-11-02 17:50 UTC